Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
APLS Stock Forecast 2026-2027
$41.03
Current Price
$5.25B
Market Cap
Buy 1
Hold 15
Sell 0
Wall St Analyst Ratings
Distance to APLS Price Targets
-0.1%
To High Target of $41.00
-0.1%
To Median Target of $41.00
-2.5%
To Low Target of $40.00
APLS Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+117.9%
1 Year Change
+63.3%
Year-to-Date Change
-0.3%
From 52W High of $41.14
+154.8%
From 52W Low of $16.10
📊 TOP ANALYST CALLS
Did APLS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Apellis is one of their latest high-conviction picks.
Latest APLS Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, APLS has a neutral consensus with a median price target of $41.00 (ranging from $40.00 to $41.00). The overall analyst rating is Buy (6.3/10). Currently trading at $41.03, the median forecast implies a -0.1% downside. This outlook is supported by 1 Buy, 15 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Derek Archila at Wells Fargo, projecting a 0.1% downside. Conversely, the most conservative target is provided by Steve Seedhouse at Cantor Fitzgerald, suggesting a 2.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APLS Analyst Ratings
1
Buy
15
Hold
0
Sell
APLS Price Target Range
Low
$40.00
Average
$41.00
High
$41.00
Current: $41.03
Latest APLS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APLS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2026 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $41.00 |
| Apr 2, 2026 | Mizuho | Graig Suvannavejh | Neutral | Maintains | $41.00 |
| Apr 1, 2026 | JP Morgan | Anupam Rama | Neutral | Downgrade | $41.00 |
| Apr 1, 2026 | Barclays | Eliana Merle | Equal-Weight | Maintains | $41.00 |
| Apr 1, 2026 | Raymond James | Ryan Deschner | Market Perform | Downgrade | $N/A |
| Apr 1, 2026 | Citigroup | Yigal Nochomovitz | Neutral | Downgrade | $41.00 |
| Apr 1, 2026 | HC Wainwright & Co. | Douglas Tsao | Neutral | Downgrade | $41.00 |
| Apr 1, 2026 | Cantor Fitzgerald | Steve Seedhouse | Neutral | Downgrade | $N/A |
| Mar 31, 2026 | Needham | Joseph Stringer | Hold | Downgrade | $N/A |
| Mar 18, 2026 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Maintains | $31.00 |
| Mar 13, 2026 | Roth Capital | Adam Walsh | Buy | Initiates | $31.00 |
| Mar 5, 2026 | JP Morgan | Anupam Rama | Overweight | Maintains | $37.00 |
| Mar 5, 2026 | Mizuho | Graig Suvannavejh | Neutral | Maintains | $20.00 |
| Feb 25, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $44.00 |
| Feb 25, 2026 | RBC Capital | Lisa Walter | Sector Perform | Maintains | $21.00 |
| Feb 25, 2026 | Wedbush | Laura Chico | Neutral | Maintains | $18.00 |
| Feb 25, 2026 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $48.00 |
| Jan 28, 2026 | Barclays | Eliana Merle | Equal-Weight | Initiates | $24.00 |
| Jan 21, 2026 | B of A Securities | Tazeen Ahmad | Buy | Upgrade | $28.00 |
| Jan 20, 2026 | Wells Fargo | Derek Archila | Overweight | Maintains | $26.00 |
Apellis Pharmaceuticals Inc. (APLS) Competitors
The following stocks are similar to Apellis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Apellis Pharmaceuticals Inc. (APLS) Financial Data
Apellis Pharmaceuticals Inc. has a market capitalization of $5.25B with a P/E ratio of 38.3x. The company generates $1.11B in trailing twelve-month revenue with a 12.1% profit margin.
Revenue growth is +60.9% quarter-over-quarter, while maintaining an operating margin of +9.9% and return on equity of +46.0%.
Valuation Metrics
Market Cap
$5.25B
Enterprise Value
$5.32B
P/E Ratio
38.3x
PEG Ratio
-0.3x
Price/Sales
4.8x
Growth & Margins
Revenue Growth (YoY)
+60.9%
Gross Margin
+84.9%
Operating Margin
+9.9%
Net Margin
+12.1%
EPS Growth
+60.9%
Financial Health
Cash/Price Ratio
+7.7%
Current Ratio
3.6x
Debt/Equity
114.7x
ROE
+46.0%
ROA
+10.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Apellis Pharmaceuticals Inc. (APLS) Business Model
About Apellis Pharmaceuticals Inc.
What They Do
Develops therapies targeting the complement system.
Business Model
The company generates revenue by discovering, developing, and commercializing therapeutic compounds that inhibit the complement system, specifically targeting rare autoimmune and inflammatory diseases. Its key products include EMPAVELI and SYFOVRE, which have received regulatory approvals for various conditions, allowing the company to capitalize on niche markets with high unmet medical needs.
Additional Information
Apellis Pharmaceuticals collaborates with other biotech firms to enhance its product development capabilities, including partnerships with Swedish Orphan Biovitrum AB and Beam Therapeutics Inc. Founded in 2009 and based in Waltham, Massachusetts, the company is positioned to advance targeted therapies in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
733
CEO
Dr. Cedric Francois M.D., Ph.D.
Country
United States
IPO Year
2017
Website
apellis.comApellis Pharmaceuticals Inc. (APLS) Latest News & Analysis
Latest News
Quick Summary
Apellis Pharmaceuticals (APLS) reported Q3 earnings of $0.15 per share, surpassing estimates of a $0.38 loss, and improved from a loss of $0.74 per share a year earlier.
Why It Matters
Apellis Pharmaceuticals' earnings beat expectations, indicating improved financial performance and potential growth, which can positively influence investor sentiment and stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics
1 month ago
Quick Summary
Apellis Pharmaceuticals (APLS) reported its quarterly performance for March 2026, highlighting key metrics compared to Wall Street estimates and previous year figures.
Why It Matters
Quarterly performance metrics against estimates and previous year figures reveal Apellis Pharmaceuticals' growth trajectory and market position, impacting stock valuation and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—CZNL, HLX, APLS, and SLNO
1 month ago
Quick Summary
Class Action Attorney Juan Monteverde's firm, recognized as a Top 50 Firm, is investigating potential shareholder claims and has recovered millions for investors.
Why It Matters
The recognition of Monteverde & Associates as a top firm in securities class actions may influence investor confidence and impact stock prices of companies involved in ongoing investigations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bright Horizons Family Solutions Inc. will replace Tri Pointe Homes in the S&P SmallCap 600 effective May 14, 2026, as Tri Pointe is being acquired by Sumitomo Forestry Group.
Why It Matters
Changes in the S&P SmallCap 600 can influence stock liquidity and investor perception. Bright Horizons' inclusion may attract investment, while Tri Pointe's acquisition could affect its stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?
1 month ago
Quick Summary
Apellis Pharmaceuticals (APLS) is anticipated to report earnings that may exceed expectations due to favorable conditions. Investors should prepare for the upcoming report.
Why It Matters
Apellis Pharmaceuticals is poised for a potential earnings beat, indicating strong performance and positive market sentiment, which could boost investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Kahn Swick & Foti is investigating the proposed sale of Apellis Pharmaceuticals to Biogen. Apellis shareholders would receive $41.00 per share plus contingent payments of $4.00 total.
Why It Matters
The investigation into Apellis Pharmaceuticals' sale to Biogen may impact shareholder sentiment and stock volatility, affecting investment decisions and potential returns.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About APLS Stock
What is Apellis Pharmaceuticals Inc.'s (APLS) stock forecast for 2026?
Based on our analysis of 24 Wall Street analysts, Apellis Pharmaceuticals Inc. (APLS) has a median price target of $41.00. The highest price target is $41.00 and the lowest is $40.00.
Is APLS stock a good investment in 2026?
According to current analyst ratings, APLS has 1 Buy ratings, 15 Hold ratings, and 0 Sell ratings. The stock is currently trading at $41.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APLS stock?
Wall Street analysts predict APLS stock could reach $41.00 in the next 12 months. This represents a -0.1% decrease from the current price of $41.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Apellis Pharmaceuticals Inc.'s business model?
The company generates revenue by discovering, developing, and commercializing therapeutic compounds that inhibit the complement system, specifically targeting rare autoimmune and inflammatory diseases. Its key products include EMPAVELI and SYFOVRE, which have received regulatory approvals for various conditions, allowing the company to capitalize on niche markets with high unmet medical needs.
What is the highest forecasted price for APLS Apellis Pharmaceuticals Inc.?
The highest price target for APLS is $41.00 from Derek Archila at Wells Fargo, which represents a -0.1% decrease from the current price of $41.03.
What is the lowest forecasted price for APLS Apellis Pharmaceuticals Inc.?
The lowest price target for APLS is $40.00 from Steve Seedhouse at Cantor Fitzgerald, which represents a -2.5% decrease from the current price of $41.03.
What is the overall APLS consensus from analysts for Apellis Pharmaceuticals Inc.?
The overall analyst consensus for APLS is neutral. Out of 24 Wall Street analysts, 1 rate it as Buy, 15 as Hold, and 0 as Sell, with a median price target of $41.00.
How accurate are APLS stock price projections?
Stock price projections, including those for Apellis Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 4:50 AM UTC